Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review

References

• DombretHRaffouxEGardinCAcute myeloid leukemia in the elderlySemin Oncol200835443043818692693
   PubMedGoogle Scholar
• JuliussonGLazarevicVHörstedtASHagbergOHöglundMSwedish Acute Leukemia Registry GroupAcute myeloid leukemia in the real world: why population-based registries are neededBlood2012119173890389922383796
   PubMed Web of Science ®Google Scholar
• Acute Myeloid Leukemia (AML) [homepage on the Internet] Available from: https://www.cancer.org/cancer/acute-myeloid-leukemia/about.htmlAccessed April, 2018
   Google Scholar
• MaynadiéMDe AngelisRMarcos-GrageraRHAEMA-CARE Working GroupSurvival of European patients diagnosed with myeloid malignancies: a HAEMACARE studyHaematologica201398223023822983589
   PubMedGoogle Scholar
• NagelGWeberDFrommEGerman-Austrian AML Study Group (AMLSG)Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Ann Hematol201796121993200329090343
   PubMed Web of Science ®Google Scholar
• KantarjianHRavandiFO’BrienSIntensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaBlood2010116224422442920668231
   PubMed Web of Science ®Google Scholar
• OhSBParkSWChungJSHematology Association of South-East Korea (HASEK) study groupTherapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapyAnn Hematol201796111801180928828639
   PubMedGoogle Scholar
• WalterRBOthusMBorthakurGPrediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignmentJ Clin Oncol201129334417442421969499
   PubMed Web of Science ®Google Scholar
• DombretHSeymourJFButrymAInternational phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood2015126329129925987659
   PubMed Web of Science ®Google Scholar
• ZiogasDCVoulgarelisMZintzarasEA network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderlyClin Ther201133325427921600383
   PubMedGoogle Scholar
• National Comprehensive Cancer NetworkNCCN Guidelines for Acute Myeloid Leukemia Version 2 ed Plymouth MeetingPANational Comprehensive Cancer Network2016 Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/aml.pdfAccessed December 20, 2018
   Google Scholar
• DöhnerHEsteyEGrimwadeDDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood2017129442444727895058
   PubMed Web of Science ®Google Scholar
• WalterRBEsteyEHManagement of older or unfit patients with acute myeloid leukemiaLeukemia201529477077525005246
   PubMed Web of Science ®Google Scholar
• LeunisARedekopWKUyl-de GrootCALöwenbergBImpaired health-related quality of life in acute myeloid leukemia survivors: a single-center studyEur J Haematol201493319820624673368
   PubMed Web of Science ®Google Scholar
• RevickiDAOsobaDFaircloughDBarofskyIBerzonRLeidyNKRothmanMRecommendations on health-related quality of life research to support labeling and promotional claims in the United StatesQual Life Res20009888790011284208
   PubMed Web of Science ®Google Scholar
• EsteyEHAcute myeloid leukemia: 2013 update on risk-stratification and managementAm J Hematol2013884317327
   Google Scholar
• LübbertMSuciuSBailaLLow-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study GroupJ Clin Oncol201129151987199621483003
   PubMed Web of Science ®Google Scholar
• BevansMHealth-related quality of life following allogeneic hematopoietic stem cell transplantationHematology Am Soc Hematol Educ Program20102010124825421239801
   PubMedGoogle Scholar
• EfficaceFNovikAVignettiMMandelliFCleelandCSHealth-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?Haematologica200792121596159818055981
   PubMedGoogle Scholar
• DeschlerBde WitteTMertelsmannRLübbertMTreatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approachesHaematologica200691111513152217082009
   PubMed Web of Science ®Google Scholar
• PitakoJAHaasPSvan den BoschJQuantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabineAnn Hematol200584Suppl 12531
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJ Clin Epidemiol20096210e1e3419631507
   PubMed Web of Science ®Google Scholar
• EfficaceFBottomleyAOsobaDGotayCFlechtnerHD’haeseSZurloABeyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making?J Clin Oncol200321183502351112972527
   PubMed Web of Science ®Google Scholar
• OlivaENSalutariPCandoniAQuality of life in elderly patients with acute myeloid leukemia undergoing induction chemotherapyBlood20151262321202120
   Google Scholar
• SekeresMALancetJEWoodBLGroveLESandalicLSieversELJurcicJGRandomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemiaHaematologica201398111912822801961
   PubMed Web of Science ®Google Scholar
• MindenMDombretHSeymourJFThe effect of azacitidine on health-related quality of life (HRQL) in older patients with newly diagnosed acute myeloid leukemia (AML): results from the AZA-AML-001 trialHaematologica2015221004041
   Google Scholar
• TsengEWellsRAAlibhaiSMThe effects of azacitidine on quality of life: a prospective longitudinal assessmentBlood2012120214938493823100310
   PubMedGoogle Scholar
• IngberSAThompsonKLamAThe effects of azacitidine on quality of life measured longitudinally in MDS patients treated at a tertiary care centerBlood20101162125712571
   Google Scholar
• OlivaENNobileFAlimenaGQuality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physiciansHaematologica201196569670221330327
   PubMedGoogle Scholar
• DeschlerBIhorstGPlatzbeckerUParameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcomeHaematologica201398220821622875615
   PubMed Web of Science ®Google Scholar
• PandyaBJHadfieldAMedeirosBCQuality of life of acute myeloid leukemia patients in a real-world settingJ Clin Oncol20173515 Supple18525
   Google Scholar
• WilliamsLAAhanekuHCortesJEComparison of symptom burden in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Blood20141242126522652
   Google Scholar
• LevyARZouDRisebroughNBucksteinRKimTBreretonNCost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromesCurr Oncol20142112940
   PubMed Web of Science ®Google Scholar
• ChengMJSmithBDHouriganCSA single center survey of health-related quality of life among acute myeloid leukemia survivors in first complete remissionJ Palliat Med201720111267127328537498
   PubMedGoogle Scholar